Jane Street
DNLI icon

Jane Street’s Denali Therapeutics DNLI Stock Holding History

Jane Street’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$617K Sell
32,147
-10,775
-25% -$214K ﹤0.01% 7548
2025
Q4 		$709K Sell
42,922
-181,981
-81% -$3.07M ﹤0.01% 6931
2025
Q3 		$3.27M Buy
224,903
+139,571
+164% +$2.01M ﹤0.01% 4082
2025
Q2 		$1.19M Sell
85,332
-128,341
-60% -$1.81M ﹤0.01% 5286
2025
Q1 		$2.9M Sell
213,673
-15,492
-7% -$297K ﹤0.01% 3763
2024
Q4 		$4.67M Sell
229,165
-140,506
-38% -$3.6M ﹤0.01% 2754
2024
Q3 		$10.8M Buy
369,671
+138,307
+60% +$3.43M ﹤0.01% 1832
2024
Q2 		$5.37M Buy
231,364
+182,648
+375% +$3.51M ﹤0.01% 2870
2024
Q1 		$1,000K Sell
48,716
-100,249
-67% -$1.88M ﹤0.01% 5414
2023
Q4 		$3.2M Buy
148,965
+110,226
+285% +$2.18M ﹤0.01% 3545
2023
Q3 		$799K Sell
38,739
-34,061
-47% -$864K ﹤0.01% 5526
2023
Q2 		$2.15M Sell
72,800
-43,005
-37% -$1.21M ﹤0.01% 4067
2023
Q1 		$2.67M Buy
115,805
+100,836
+674% +$2.78M ﹤0.01% 3343
2022
Q4 		$416K Buy
+14,969
New +$445K ﹤0.01% 6456
2022
Q3 		– Sell
-13,923
Closed -$410K – 9832
2022
Q2 		$410K Buy
+13,923
New +$365K ﹤0.01% 7085
2022
Q1 		– Sell
-24,456
Closed -$1.09M – 10422
2021
Q4 		$1.09M Buy
24,456
+5,759
+31% +$273K ﹤0.01% 5713
2021
Q3 		$943K Buy
18,697
+14,384
+334% +$811K ﹤0.01% 6026
2021
Q2 		$338K Sell
4,313
-8,668
-67% -$536K ﹤0.01% 7941
2021
Q1 		$741K Sell
12,981
-19,613
-60% -$1.31M ﹤0.01% 6050
2020
Q4 		$2.73M Buy
32,594
+2,748
+9% +$166K ﹤0.01% 2951
2020
Q3 		$1.07M Buy
29,846
+6,919
+30% +$208K ﹤0.01% 3994
2020
Q2 		$554K Sell
22,927
-16,039
-41% -$377K ﹤0.01% 4921
2020
Q1 		$683K Buy
+38,966
New +$813K ﹤0.01% 3286
2019
Q4 		– Sell
-12,976
Closed -$199K – 5160
2019
Q3 		$199K Buy
+12,976
New +$248K ﹤0.01% 4652
2018
Q4 		– Sell
-10,020
Closed -$218K – 5077
2018
Q3 		$218K Buy
+10,020
New +$166K ﹤0.01% 4590

Other funds holding DNLI

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Jane Street's DNLI Position: Q1 2026 in Review

Jane Street reduced its Denali Therapeutics (DNLI) stake by 25% in Q1 2026, selling an estimated $214K and leaving 32,147 shares worth $617K. The position accounts for ﹤0.01% of the portfolio, ranked #7548.

Jane Street first reported a position in DNLI in Q3 2018 and has held it in 25 quarters since. The position peaked at $10.8M in Q3 2024. 269 funds tracked by Wall St. Rank hold DNLI as of Q1 2026.

  • Jane Street held 32,147 shares of Denali Therapeutics worth $617K as of Q1 2026.
  • Jane Street sold 10,775 Denali Therapeutics shares in Q1 2026, an estimated $214K.
  • Denali Therapeutics made up ﹤0.01% of Jane Street's portfolio in Q1 2026, its #7548 holding.
  • Jane Street first reported a position in Denali Therapeutics in Q3 2018 and has held it in 25 quarters since.
  • Jane Street's Denali Therapeutics position peaked at $10.8M in Q3 2024.
  • 269 funds tracked by Wall St. Rank held Denali Therapeutics as of Q1 2026.

Based on Jane Street's 13F filing for Q1 2026, filed 12 May 2026.